Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



JOURNAL OF THORACIC ONCOLOGY
ISSN 1556-0864
E-ISSN 1556-1380
País S/I
Indexación WoS Scopus

Publicaciones Chile en el período 2008-2021

Autores Chile en el período 2008-2021


Factor de Impacto WoS



Año Factor de Impacto
2011 3.661
2012 4.473
2013 4.473
2014 5.282
2015 5.04
2016 6.595
2017 10.336
2018 12.46
2019 13.357
2020 13.357
2021 13.357

Muestra el factor de impacto de la revista seleccionada en el tiempo.

Disciplinas y Ranking



Año Ranking Cuartil

Muestra la distribución de disciplinas para la revista.

Cuartiles desplegados de acuerdo a WoS, consultando el Journal Citation Report. Estos cuartiles pueden variar dependiendo de la disciplina consultada.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Origen de las citas recibidas por la revista


Nombre Revista ISSN/ISBN Indexacion Citas
Journal of Thoracic Oncology 1556-0864 WOS, Scopus 5
FRONTIERS IN PHARMACOLOGY 1663-9812 Externa 1
MEDICINE 0025-7974 Externa 1
PLOS ONE 1932-6203 Externa 1
DRUGS 0012-6667 Externa 1
BIOMED RESEARCH INTERNATIONAL 2314-6133 Externa 1
NATURAL PRODUCT REPORTS 0265-0568 Externa 1
NEW ENGLAND JOURNAL OF MEDICINE 0028-4793 Externa 2
EXPERT OPINION ON PHARMACOTHERAPY 1465-6566 Externa 1
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 0223-5234 Externa 1
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 1619-7070 Externa 1
HISTOPATHOLOGY 0309-0167 Externa 1
COCHRANE DATABASE OF SYSTEMATIC REVIEWS 1469-493X Externa 2
PHARMACOTHERAPY 0277-0008 Externa 1
ANNALS OF ONCOLOGY 0923-7534 Externa 1
CANCER 0008-543X Externa 2
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE 1940-5901 Externa 1
FRONTIERS IN BIOSCIENCE-LANDMARK 1093-9946 Externa 1
CURRENT ONCOLOGY 1198-0052 Externa 2
CHINESE MEDICAL JOURNAL 0366-6999 Externa 1
POSTGRADUATE MEDICAL JOURNAL 0032-5473 Externa 1
ADVANCES IN THERAPY 0741-238X Externa 1
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1422-0067 Externa 2
ONCOLOGIST 1083-7159 Externa 2
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 0735-1097 Externa 1
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 1128-3602 Externa 1
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 1040-8428 Externa 1
GENES 2073-4425 Externa 1
ONCOTARGETS AND THERAPY 1178-6930 Externa 2
CURRENT TOPICS IN MEDICINAL CHEMISTRY 1568-0266 Externa 1
FRONTIERS IN MEDICINE 2296-858X Externa 1
NATURE COMMUNICATIONS 2041-1723 Externa 1
FRONTIERS IN IMMUNOLOGY 1664-3224 Externa 1
EXPERT OPINION ON BIOLOGICAL THERAPY 1471-2598 Externa 1
ANNALS OF TRANSLATIONAL MEDICINE 2305-5839 Externa 3
JOURNAL OF CLINICAL ONCOLOGY 0732-183X Externa 3
CANCER MANAGEMENT AND RESEARCH 1179-1322 Externa 1
JOURNAL FOR IMMUNOTHERAPY OF CANCER 2051-1426 Externa 1
FRONTIERS IN ONCOLOGY 2234-943X Externa 3
NEUROCHEMICAL RESEARCH 0364-3190 Externa 1
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2164-5515 Externa 1
ENVIRONMENT INTERNATIONAL 0160-4120 Externa 1
FRONTIERS IN CARDIOVASCULAR MEDICINE 2297-055X Externa 1
CANCER COMMUNICATIONS 2523-3548 Externa 1
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE 1753-4658 Externa 1
TRANSLATIONAL LUNG CANCER RESEARCH 2218-6751 Externa 7
LUNG CANCER 0169-5002 Externa 6
TRANSLATIONAL CANCER RESEARCH 2218-676X Externa 2
JOURNAL OF THORACIC DISEASE 2072-1439 Externa 7
NATURE REVIEWS CLINICAL ONCOLOGY 1759-4774 Externa 3
FUTURE ONCOLOGY 1479-6694 Externa 4
ONCOIMMUNOLOGY 2162-402X Externa 2
THORACIC CANCER 1759-7706 Externa 1
EXPERIMENTAL HEMATOLOGY & ONCOLOGY 2162-3619 Externa 1
UROLOGICAL SCIENCE 1879-5226 Externa 1
CLINICAL & TRANSLATIONAL ONCOLOGY 1699-048X Externa 2
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY 1758-8340 Externa 1
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY 1543-0790 Externa 2
EXPERT REVIEW OF ANTICANCER THERAPY 1473-7140 Externa 3
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 0171-5216 Externa 1
ANTICANCER RESEARCH 0250-7005 Externa 1
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION 1726-4901 Externa 1
ONCOLOGY RESEARCH AND TREATMENT 2296-5270 Externa 1
CELL REPORTS 2211-1247 Externa 1
EXPERT REVIEW OF RESPIRATORY MEDICINE 1747-6348 Externa 2
MOLECULAR CANCER 1476-4598 Externa 1
IMMUNOTHERAPY 1750-743X Externa 1
CLINICAL CANCER RESEARCH 1078-0432 Externa 1
BRITISH JOURNAL OF CANCER 0007-0920 Externa 2
CURRENT OPINION IN OPHTHALMOLOGY 1040-8738 Externa 1
HERZ 0340-9937 Externa 1
ONCOLOGY LETTERS 1792-1074 Externa 1
JOURNAL OF CELLULAR PHYSIOLOGY 0021-9541 Externa 1
DRUG DISCOVERY TODAY 1359-6446 Externa 1
INVESTIGATIONAL NEW DRUGS 0167-6997 Externa 1
EUROPEAN JOURNAL OF CANCER 0959-8049 Externa 1
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 0022-3565 Externa 2
FRONTIERS IN PEDIATRICS 2296-2360 Externa 1
IJC HEART & VASCULATURE 2352-9067 Externa 1
CURRENT CARDIOVASCULAR IMAGING REPORTS 1941-9066 Externa 1
DRUG RESISTANCE UPDATES 1368-7646 Externa 1
LUNG CANCER-TARGETS AND THERAPY 1179-2728 Externa 1
INTERNATIONAL IMMUNOPHARMACOLOGY 1567-5769 Externa 1
EXPERT OPINION ON INVESTIGATIONAL DRUGS 1354-3784 Externa 1
CLINICAL LUNG CANCER 1525-7304 Externa 1
TRENDS IN GENETICS 0168-9525 Externa 1
CANCER MEDICINE 2045-7634 Externa 2
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE 1069-3424 Externa 1
HUMAN CELL 0914-7470 Externa 1
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 1743-7555 Externa 1
CLINICAL DRUG INVESTIGATION 1173-2563 Externa 1
CURRENT RESPIRATORY MEDICINE REVIEWS 1573-398X Externa 1
JAMA ONCOLOGY 2374-2437 Externa 2
GENE REPORTS 2452-0144 Externa 1
MOLECULAR THERAPY 1525-0016 Externa 1
FUTURE SCIENCE OA 2056-5623 Externa 1
CURRENT TREATMENT OPTIONS IN ONCOLOGY 1527-2729 Externa 1
BIOLOGY & PHILOSOPHY 0169-3867 Externa 1
ENVIRONMENTAL TECHNOLOGY & INNOVATION 2352-1864 Externa 1
CANCER CHEMOTHERAPY AND PHARMACOLOGY 0344-5704 Externa 1
CURRENT CLINICAL PHARMACOLOGY 1574-8847 Externa 1
NEURO-OPHTHALMOLOGY 0165-8107 Externa 1
CLINICAL MEDICINE INSIGHTS-ONCOLOGY 1179-5549 Externa 1
PHARMACEUTICAL RESEARCH 0724-8741 Externa 1
MABS 1942-0862 Externa 1
ACTA OTO-LARYNGOLOGICA 0001-6489 Externa 1
ONCOTARGET 1949-2553 Externa 3
CURRENT PROBLEMS IN CANCER 0147-0272 Externa 1
KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY 1731-5530 Externa 1
CANCER SCIENCE 1349-7006 Externa 1
SOUTH ASIAN JOURNAL OF CANCER 2278-330X Externa 1
THERAPEUTIC INNOVATION & REGULATORY SCIENCE 2168-4790 Externa 2
INDIAN JOURNAL OF CANCER 0019-509X Externa 1
MARINE FUNGI AND FUNGAL-LIKE ORGANISMS 978-3-11-026398-5 Externa 1

Listado ordenado (según número de citas) de Revistas que citan a la revista consultada en este perfil.

: Las citas a esta revista provienen de documentos no incluidos en la base de datos de DATACIENCIA

Publicaciones


Título Año Citas
Panorama Retro: Real World Evaluation Of Molecular Testing And Treatment Patterns For Egfr Mutations In Patients With Advanced Or Metastatic Nsclc (D133 Fr00143) 2019 0
Prospective Epidemiological Study Of Metastatic Non Small Cell Lung Cancer (Nsclc) In Latin America Latino Lung (Lacog 0116) 2019 0
Effectiveness Of Second Line Treatment With Nintedanib Plus Docetaxel (Nd) In Patients With Metastatic Lung Adenocarcinoma 2019 0
Lung Cancer In Lleida: An Epidemiologic Study 2019 0
Mesothelioma Survival In 2 Health Centres In Santiago De Chile 2019 0
Early And Late Survival Comparison Between Oncological Versus Non Oncological Patients Admitted To A General Intensive Care Unit In Chile 2019 0
Check Mate 817: First Line Nivolumab Plus Ipilimumab In Patients With Ecog Ps 2 And Other Special Populations With Advanced Nsclc 2019 37
Five Year Outcomes From The Randomized, Phase 3 Trials Check Mate 017/057: Nivolumab Vs Docetaxel In Previously Treated Nsclc 2019 29
Lung Cancer In Chile 2019 1
Immune Checkpoint Inhibitor Associated Pericarditis 2019 51
Nivolumab Versus Docetaxel In Patients With Previously Treated Advanced Non Small Cell Lung Cancer And Liver Metastases 2017 0
Multicenter Assessment Of Pd L1 Immunohistochemistry: Challenges For Establishing The Concordance Between Four Different Antibodies 2017 0
Clinical Significance Of The Tumor Expression Of Pd L1 Using Four Immunohistochemistry Assays In Non Small Cell Lung Cancer. Multicentre Study 2017 0
Lung Cancer Surgery For High Risk Patients 2017 0
Early Stage Non Small Cell Lung Cancer Survival In A Chilean Private Teaching Hospital 2018 0
Immunologic Characterization Of Fibrinous Pericarditis As An Immune Checkpoint Blockade Toxicity In Nsclc 2018 0
Prevalence Of Egfr Alterations In Chilean Lung Cancer Patients: A Retrospective Study 2018 0
I Mpower132: Pfs And Safety Results With 1 L Atezolizumab Plus Carboplatin/Cisplatin Plus Pemetrexed In Stage Iv Non Squamous Nsclc 2018 96
Avelumab Vs Docetaxel For Previously Treated Advanced Nsclc: Primary Analysis Of The Phase 3 Javelin Lung 200 Trial 2018 0
Nintedanib Plus Pemetrexed/Cisplatin In Patients With Unresectable Mpm: Phase Iii Results From The Lume Meso Trial 2018 1
75 Mg Of Erlotinib In Latin American Patients With Metastatic Non Small Cell Lung Cancer Long Term Analysis 2018 0
Preliminary Experience With The Use Of Osimertinib In Chilean Patients 2018 0
Molecular Characterization Of Egfr Somatic Mutations In Lung Adenocarcinoma Tumors From Chilean Patients 2018 0
Preliminary Orthogonal Analysis Of Eml4 Alk Gene Fusion Detection Methods In Chilean Patients With Lung Adenocarcinoma 2018 0
A Comprehensive Description Of The Molecular Epidemiology Of Somatic Mutations In Actionable Genes In Nsclc Chilean Patients 2018 0
Primary Pfs And Safety Analyses Of A Randomized Phase Iii Study Of Carboplatin Plus Paclitaxel Plus / Bevacizumab, With Or Without Atezolizumab In 1 L Non Squamous Metastatic Nsclc (I Mpower150) 2018 6
Preliminary Assessment Of A Targeted Break Point Ngs Assay For Alk Gene Fusion Detection In Lung Adenocarcinoma Samples From Chilean Patients 2018 0
Pembrolizumab Vs Docetaxel For Previously Treated Nsclc (Keynote 010): Archival Vs New Tumor Samples For Pd L1 Assessment 2016 9
Pembrolizumab Vs Docetaxel For Previously Treated Nsclc (Keynote 010): Archival Vs New Tumor Samples For Pd L1 Assessment 2016 3
First Line Durvalumab Plus Tremelimumab Vs Platinum Based Chemotherapy For Advanced/Metastatic Nsclc: Phase 3 Neptune Study 2017 3
Long Term Survival Of Lung Cancer In Chile 2017 1
Neptune: A Global, Phase 3 Study Of Durvalumab (Medi4736) Plus Tremelimumab Combination Therapy Versus Standard Of Care (So C) Platinum Based Chemotherapy In The First Line Treatment Of Patients (Pts) With Advanced Or Metastatic Nsclc 2016 29
Cf Dna In Lung Cancer Patients And People With High Risk Of Lc Exposed To Environmental Pollution 2015 0
Randomized Phase 2 Study Of Plinabulin And Docetaxel In Patients With Advanced Non Small Cell Lung Cancer Mechanism Based Efficacy Analyses 2015 0
Detection Of Mutations In Tumor And Blood Samples From Lung Adenocarcinoma Patients Using Two Different Techniques 2015 0
Phase 3, Randomized Trial (Check Mate 017) Of Nivolumab (Nivo) Vs Docetaxel In Advanced Squamous (Sq) Cell Non Small Cell Lung Cancer (Nsclc) 2015 7
Monotherapy Administration Of Sorafenib In Patients With Non Small Cell Lung Cancer (Mission) Trial A Phase Iii, Multicenter, Placebo Controlled Trial Of Sorafenib In Patients With Relapsed Or Refractory Predominantly Nonsquamous Non Small Cell Lung Cancer After 2 Or 3 Previous Treatment Regimens 2015 71
Early Experience With Thoracoscopic Resection Of Small Pulmonary Nodules With Pre Operative Lipiodol Marking. 2014 0
Free Circulating Dna Levels In Individuals With Lung Cancer Risk And Characterization Of Copy Number Alterations. 2014 0
Design, Implementation And Preliminary Results Of A Tobacco Cessation Program In A Private Clinic 2014 2
Genomic Alteration In Sputum Samples And Dnafc Of Lung Cancer High Risk Chilean Population 2013 0
Concurrent Chemoradiation (Cchrt) For Stage Iii Non Small Cell Lung Cancer (Nsclc): A Phase Ii Study From The Galician Lung Cancer Group 2013 0
Multi 'Omic Analysis Of An Arsenic Associated Lung Squamous Cell Carcinoma Reveals Specific Dna Level Signatures 2013 0
Whole Genome Sequencing Analysis Identifies A Distinctive Mutational Spectrum In An Arsenic Related Lung Tumor 2013 13
Stereotactic Ablative Image Guided Helical Tomotherapy For Pulmonary Oligometastasis 2012 0
Malignant Pleural Mesothelioma And Ercc1 Expression 2012 0
Diagnosis Of Pleural Diseases Using Inmunohistochemistry (Ih) On Celular Block (Cb) In Alcohol Preserved Malignant Pleural Effusion: A Descriptive Study 2012 0
Low Dose Erlotinib As First Line Treatment In Metastatic Lung Adenocarcinoma With Egfr Mutation 2012 0
Metastatic Non Small Cell Lung Cancer (Nsclc) With More Than 3 Years Survival 2012 0
Biological Biomarkers For Screening Of Pre Neoplastic Lesions Associated To Lung Cancer In A Risk Chilean Population 2012 0
Non Small Cell Lung Cancer(nsclc) With Activating Egfr Mutation In Chile 2011 1
Outcome Of Metastatic Non Small Cell Lung Carcinoma Patients Receiving Systemic Treatment: A Single Latinamerican Institution Experience 2010 0
Plinabulin (Npi 2358), A Novel Vascular Disrupting Agent (Vda), In Non Small Cell Lung Cancer (Nsclc) 2010 3
Sancomatoid Carcinoma (Sc) Associated To Hypertrophic Pulmonary Osteoarthropathy (Hpo) 2009 0
A Data Base Of Lung Cancer From The Instituto Nacional Del Torax (Int) (1994 19999): Its Value For Surgical Treatment And Follow Up 2009 0
Progress In The Management Of Small Cell Lung Cancer (Sclc) In The Instituto Nacional Del Torax (Int). Chile 2009 0
Pembrolizumab Plus Ipilimumab Vs Pembrolizumab Plus Placebo As 1 L Therapy For Metastatic Nsclc Of Pd L1 Tps ≥50%: Keynote 598 2021 0
Durvalumab In Locally Advanced Nsclc In Latam: Real World Data From Patients Included In The Early Access Program 2021 0
Keynote 042 3 Year Survival Update: 1 L Pembrolizumab Vs Platinum Based Chemotherapy For Pd L1+Locally Advanced/Metastatic Nsclc 2021 17
Atezolizumab Plus Chemotherapy For First Line Treatment Of Nonsquamous Nsclc: Results From The Randomized Phase 3 I Mpower132 Trial 2021 181
First Line Nivolumab Plus Ipilimumab Versus Chemotherapy In Advanced Nsclc With 1% Or Greater Tumor Pd L1 Expression: Patient Reported Outcomes From Check Mate 227 Part 1 2021 28
Avelumab Versus Docetaxel In Patients With Platinum Treated Advanced Nsclc: 2 Year Follow Up From The Javelin Lung 200 Phase 3 Trial 2021 24
I Mpower150 Final Overall Survival Analyses For Atezolizumab Plus Bevacizumab And Chemotherapy In First Line Metastatic Nonsquamous Nsclc 2021 147
Blood First Assay Screening Trial (Bfast) In Treatment Naive Advanced Or Metastatic Nsclc : Initial Results Of The Phase 2 Alk Positive Cohort 2021 15
I Mpower150 Final Exploratory Analyses For Atezolizumab Plus Bevacizumab And Chemotherapy In Key Nsclc Patient Subgroups With<I> Egfr</I> Mutations Or Metastases In The Liver Or Brain 2022 79
First Line Nivolumab Plus Ipilimumab In Advanced Nsclc: 4 Year Outcomes From The Randomized, Open Label, Phase 3 Check Mate 227 Part 1 Trial 2022 122
The International Association For The Study Of Lung Cancer Lung Cancer Staging Project: Overview Of Challenges And Opportunities In Revising The Nodal Classification Of Lung Cancer 2023 3
Systematic Population Based Identification Of Ntrk Fusion Genes Among Hispanic Patients With Non Small Cell Lung Cancer (Nsclc) 2022 0
Hispanic Patients With Unresectable Stage Iii Nsclc Under Pacific Protocol: Evidence Of Interior Outcomes And Health Inequity 2022 0
Mechanisms Of Resistance To First Line Osimertinib In Hispanic Patients With Egfr Mutant Non Small Cell Lung Cancer (Freston Cli Ca P∫) 2022 0
The Evolution Of Lung Neuroendocrine Tumors 2022 0
First Line Pembrolizumab Or Placebo Combined With Etoposide And Platinum For Es Sclc: Keynote 604 Long Term Follow Up Results 2022 4
First Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone For Metastatic Nsclc In Check Mate 9 La: 3 Year Clinical Update And Outcomes In Patients With Brain Metastases Or Select Somatic Mutations 2023 0
Understanding Therapeutic Trajectories Of Adults With Lung Cancer In Chile: A Multi Methods Study Of Time To Diagnosis And Perceived Experience 2023 0
Gender Differences In Lung Cancer In Chile 2023 0
Genomic Landscape Of Primary Resistance To Osimertinib Among Hispanic Patients With Egfr Mutant Non Small Cell Lung Cancer: Results Of An Observational Longitudinal Cohort Study 2023 0
First Line Nivolumab Plus Ipilimumab Plus Chemotherapy In Metastatic Nsclc: Check Mate 9 La 3 Year Update 2023 0
Safety And Efficacy Of Tusamitamab Ravtansine In Combination With Pembrolizumab ± Chemotherapy In Patients With Ceacam5 Positive Nonsquamous Nsclc (Carmen Lc05 Phase Ii Study) 2023 0
Systemic And Intracranial Outcomes With First Line Nivolumab Plus Ipilimumab In Patients With Metastatic Nsclc And Baseline Brain Metastases From Check Mate 227 Part 1 2023 2
Brigatinib Versus Alectinib In Alk Positive Nsclc After Disease Progression On Crizotinib: Results Of Phase 3 Alta 3 Trial 2023 4
Impact Of Concurrent Genomic Alterations On Clinical Outcomes In Patients With Alk Rearranged Nsclc 2024 0
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed By Adjuvant Durvalumab In Resectable Nsclc (Aegean) 2023 0
Cd47 As Biomarker Of Prognosis In Patients With Malignant Pleural Mesothelioma 2023 0
Co Occurring Loss Of Cdkn2 A/2 B Associated With Worse Survival And Increase Risk Of Brain Metastasis In Alk Rearranged Non Small Cell Lung Cancer 2023 0
The International Association For The Study Of Lung Cancer Staging Project For Lung Cancer: Proposals For The Revision Of The N Descriptors In The Forthcoming Ninth Edition Of The Tnm Classification For Lung Cancer 2024 0
The International Association For The Study Of Lung Cancer Staging Project For Lung Cancer: Proposals For The Revision Of The M Descriptors In The Forthcoming Ninth Edition Of The Tnm Classification For Lung Cancer 2024 0
Brief Report: Updated Data From I Mscin001 Part 2, A Randomized Phase Iii Study Of Subcutaneous Versus Intravenous Atezolizumab In Patients With Locally Advanced Or Metastatic Nsclc 2024 0

Listado de publicaciones y sus citas para la revista seleccionada.

Descargar Descarga los datos de esta página (formato JSON).
Descargar Descarga los datos de esta página como un archivo Excel.









Departamento Gestión de Conocimiento, Monitoreo y Prospección
 Moneda 1375, Santiago de Chile. Teléfono (56 2) 2365 4400
Consultas o comentarios: productividad@anid.cl